Novartis’ CTL019, the immunotherapy treatment that’s seeing tremendous results in achieving remission for leukemia patients, was awarded “breakthrough” status by the FDA, a rare laurel that’s speeding up its review.
CTL019 was developed by U. Penn. researcher Dr. Carl June, an ACGT fellow and Scientific Advisory Council member. Read the Greenwich Time story here, and view a clip of Dr. June speaking to ACGT supporters here.